Femasys is a small, pre-profitability medical device company focused on women's reproductive health. Femasys develops in-office, non-surgical alternatives to procedures that traditionally require specialist referrals or operating rooms, selling single-use disposable device kits to gynecologists and reproductive endocrinologists. Each procedure consumes a device, creating a recurring revenue stream tied to procedure volume. Femasys has two core product lines. FemaSeed, its commercial product, is a device for intratubal insemination — an artificial insemination method that delivers sperm directly into the fallopian tube rather than the uterus, as in traditional IUI. FemaSeed is sold alongside FemVue, a companion diagnostic that confirms fallopian tube patency via ultrasound, and FemSperm, a kit enabling gynecologists to prepare and analyze sperm in-office. FemBloc, its pipeline product approved in the EU, UK, and New Zealand but still awaiting U.S. FDA clearance, is a non-surgical permanent birth control system that delivers a biodegradable polymer into the fallopian tubes in-office, causing permanent blockage via scar tissue — with no incision, anesthesia, or implant. FemBloc's FDA pivotal trial enrolled its final phase in March 2026. Femasys manufactures all products at its Suwanee, Georgia facility, uses a direct U.S. sales force of roughly 10 reps, and relies on distribution partners internationally. The company has raised over $170M since inception to fund R&D and clinical trials, with FemBloc's FDA approval representing the key commercial catalyst.